• Press Office

    Posted in category News Release by Press Office on 23/07/2012

    New Medical, Innovation and Research Director completes Whitehead’s top team

The ABPI has named its new Medical, Innovation and Research Director as Dr Bina Rawal, who will join the trade body’s top team in October.


Bina will be the senior medical spokesperson for the research-based UK pharmaceutical industry to government, the media and professional organisations and will be responsible for advancing the productivity of the innovation process in the UK to build the UK’s position in the global industry.

Bina joins the ABPI from the Wellcome Trust where in her role as Head of Clinical Development within the Technology Transfer Division (TTD) she has been responsible for oversight and governance of the clinical pipeline. The TTD portfolio, derived from the funding of translational research, clinical validation and the development of new health care products includes small molecule and biological therapeutics, vaccines, medical devices, diagnostics, regenerative medicine programs and enabling technologies. Prior to joining the Wellcome Trust, Bina has held senior roles at Roche and GlaxoWellcome R&D.

Stephen Whitehead, ABPI CEO, said:

"Bina joins our senior team at a critical time for industry when we need to demonstrate the very high value of the UK’s research and development capability in the pharmaceutical industry on the global stage. We need a strong voice for innovation in the industry and Bina’s experience and background will complement that of our members’ to champion science, discovery, research and development and enable it to thrive in the UK."

Recently appointed chair of the ABPI’s Innovation Board Neil Weir (UCB) said:

"We’re delighted that Bina will lead the Medical and Innovation Team at the ABPI and work with members to drive the agenda for innovation in the UK. The ABPI has a great track record of supporting and advocating for scientific and medical innovation in the UK and Bina’s appointment signals our continuing commitment."

Dr Bina Rawal said:

"I am very pleased to be joining the ABPI team and members to lead the campaigns on innovation. The pharmaceutical industry plays a vital role as a health care provider in the UK and research and development are an integral part of the patient journey through the NHS. I am very excited about working with members, the Innovation Board and many stakeholders to demonstrate and enhance this contribution for the benefit of patients and the UK economy."


Media enquiries

ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Email: pressoffice@abpi.org.uk


Notes to editors

Dr Bina Rawal FFPM, FRCPath
Head of Clinical Development, Wellcome Trust: Aug 2009 – 2012
Therapeutic Area Expert, Roche Products Ltd: Jul 2007 – Jun 2009
Site Head, PDCV, Clinical Research & Licensing Liaison, Roche Products Ltd: Mar 2000 – Jun 2007
Senior Medical Strategy Head, Influenza, GlaxoWellcome R&D: Feb 1998 – Feb 2000
Associate Medical Director, GlaxoWellcome UK: Mar 1996 – Jan 1998
Medical Strategy Manager, Glaxo R&D: Nov 1993 – Feb 1996
Career progression, NHS: Aug 1985 – Oct 1993



Fellowship of the Faculty of Pharmaceutical Medicine 2010
Diploma in Pharmaceutical Medicine, University of Wales 1999
Membership of the Royal College of Pathologists (1992), converted to Fellowship in 1999
MSc. Virology (Distinction), University of London 1989
MBBS, University of London 1985
BSc Hons (First Class) in Infection and Immunity, University of London 1982


The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. 

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases. 

We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.